LETTERS TO THE EDITOR
REVISTA DE LA FACULTAD DE MEDICINA HUMANA 2020 - Universidad Ricardo Palma
1Universidad Nacional Mayor de San Marcos. Lima, Perú.
Dear Editor
Currently the coronavirus (COVID-19) infection has become a public health problem worldwide. In December 2019, in the city of Wuhan, province of Hubei, China, the first cases of pneumonia of unknown etiology
were reported, which incremented rapidly in other provinces of the country.(1)
Subsequently, SARS-CoV2 was identified as the causal agent and in mid-January 2020, the World Health Organization (WHO) reported over 280 confirmed cases of COVID-19 in China, Thailand, Japan and Korea.(2)
In South America, the first case of COVID-19 is made known on February 26, 2020 in the city of Sao Paulo, Brazil, identified as a male patient of 61 years of age from the region of Lombardy in Italy. Soon after there were other confirmed
cases imported from the Asian and European continents in other south American countries.(3)
Up until April 14, 2020, there have been 1.983.219 COVID-19 cases reported worldwide, of which 2.84% are found in South America. Brazil is the country that has the greatest number of people infected (24,232), concentrated mainly in
Sao Paulo and Rio de Janeiro. Peru is second place with 10,303 confirmed cases, with numbers multiplying in the last 5 days. This increase is affected by the number of tests performed and the lack of adherence to measures established by the
government by one group of the population, causing conglomerations in the supermarkets, markets and public transport.
In Peru, men represent 73.9% of total COVID-19 confirmed cases, with the majority of those infected in the country’s capital (Lima), a tendency that is repeated in other Latin American capitals, while in Chile 50.09% of positive cases
correspond to the female gender. The comorbidities identified with greater frequency in fatal cases were cardiovascular diseases (hypertension) and diabetes mellitus (Peru, Chile and Brazil). (4,5)
As far as mortality from COVID-19 in South America, Ecuador takes the lead, presenting so far, a mortality rate of 2 per 100 thousand inhabitants, followed by Peru with 0.7 per 100 thousand inhabitants.
Despite Chile being one of the South American countries that concentrates the majority of SARS-CoV2 infected people, it has the lowest fatality rate in the region (1.6%), followed by Uruguay, even lower than Japan (1.87%). This is
due to the measures their authorities have taken to stop the spread of disease which includes the ability to identify infected patients and isolate them early on, a strategy that the World Health Organization has emphasized; achieving so far
the greatest number of tests per million inhabitants in the region, after Venezuela. Currently Peru has adapted these measures aggressively and is the second country with greater number of diagnostic tests in Latin America, with 102,2016 between
rapid tests and molecular tests. See Table 1
TABLE 1. Statistical data on COVID-19 in South America, 2020
Countries in South America |
First reported case |
Quarantine onset |
Confirmed cases |
Deaths |
Fatality |
Total Tests |
Tests/ Million |
ARGENTINA |
March 3 |
March 20 |
2,277 |
102 |
4.47% |
22,805 |
505 |
BOLIVIA |
March 10 |
March 22 |
354 |
28 |
7.90% |
2,185 |
187 |
BRASIL |
February 26 |
March 19 closed borders |
24,232 |
1,378 |
5.68% |
62,985 |
296 |
CHILE |
March 3 |
March 18 state of emergency |
7,917 |
92 |
1.16% |
87,794 |
4,593 |
COLOMBIA |
March 6 |
March 24 |
2,852 |
112 |
3.92% |
43,053 |
846 |
ECUADOR |
February 29 |
March 16 state of emergency |
7,603 |
355 |
4.66% |
25,347 |
1,437 |
PARAGUAY |
March 7 |
March 10 |
159 |
7 |
4.40% |
3,394 |
476 |
PERÚ |
March 6 |
March 15 |
10,303 |
230 |
2.23% |
102,216 |
3,100 |
URUGUAY |
March 13 |
No quarantine |
483 |
8 |
1.65% |
9,236 |
2,659 |
VENEZUELA |
March 13 |
March 17 |
189 |
9 |
4.76% |
203,108 |
7,143 |
TOTAL |
|
|
56,369 |
2,321 |
4.11% |
|
|
Author contributions: The authors participated in the genesis of the idea, data collection and interpretation and manuscript preparation of the present research work.
Financing: Self-financed.
Conflict of interests: The authors declare not to have any conflict of interests.
Received: April 15, 2020
Approved: May 22, 2020
Correspondence:Echeverría Ibazeta, R. Rainer
Address: Dirección: H.H. Buenos Aires 1713 Bellavista, Callao, Perú
Telephone number: +51 970 094 986
Email: r.rainer.echeverria@gmail.com